Chris Garabe­di­an's in­cu­ba­tor leads Se­ries A fund­ing for gene ther­a­py man­u­fac­tur­er/de­vel­op­er com­bo

Back in De­cem­ber, long­time in­dus­try in­vestor Chris Garabe­di­an helped launch a $210 mil­lion VC fund for ear­ly-stage biotechs. On Tues­day, Garabe­di­an and the Per­cep­tive Xon­toge­ny Ven­ture Fund in­tro­duced its lat­est start­up.

The ex-Sarep­ta CEO has teamed with for­mer Abeona chief Tim Miller to cre­ate Forge Bi­o­log­ics, a gene ther­a­py com­pa­ny fo­cus­ing on both man­u­fac­tur­ing and de­vel­op­ment of GMP ade­no-as­so­ci­at­ed virus­es, with $40 mil­lion in Se­ries A fund­ing. Forge is the eighth biotech in which the PXV Fund has in­vest­ed — but on­ly the sixth an­nounced — and the first in the gene ther­a­py area, Garabe­di­an told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER